Your session is about to expire
← Back to Search
Zilovertamab Vedotin for Lymphoma
Study Summary
This trial will test how well a new cancer drug called zilovertamab vedotin works and how safe it is.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of hepatitis B or active hepatitis C.I have had an organ transplant.My organs are functioning well.I have been diagnosed with HIV.I have had serious heart problems or irregular heartbeat needing medication in the last 6 months.I have persistent nerve pain or tingling in my hands or feet.I have had a stem cell transplant and am experiencing complications.I am taking more than 30 mg of corticosteroids daily.My lymphoma has spread to my brain or spinal cord.My DLBCL has not responded to at least 2 treatments, including a stem cell transplant or I'm ineligible for one.I haven't had cancer treatment or experimental drugs in the last 4 weeks.I had radiotherapy within the last 28 days and have recovered from side effects.I have a known history of liver cirrhosis.I either did not respond to CAR-T therapy or am not eligible for it.I had another cancer but was treated successfully and have been cancer-free for 2 years.I have fluid around my heart or in my lungs.My DLBCL can be measured using scans.My physical ability was assessed as able to care for myself up to being up and about more than half of waking hours, within the last week.My lymphoma has changed from a slow-growing type to a more aggressive form.I have not received a live vaccine in the last 30 days.You are expected to live for at least 3 more months.I have been diagnosed with Primary mediastinal B-cell lymphoma.I have been diagnosed with diffuse large B-cell lymphoma.I am currently being treated for an infection.
- Group 1: Arm A
- Group 2: Arm B
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has MK-2140 (zilovertamab vedotin) been formally sanctioned by the FDA?
"There is a limited amount of evidence suggesting the safety of MK-2140 (zilovertamab vedotin), thus it received an assessment score of 2. No data exists that confirms its efficacy."
How many institutes are participating in the experiment?
"The clinical trial is being conducted in multiple sites throughout the US, including AHN West Penn Hospital (Site 0212) in Pittsburgh, Pennsylvania; Saint Louis University Cancer Center ( Site 0209) in St. Louis, Missouri; and St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229) located in Orange , California amongst 16 other locations."
How many volunteers are participating in this research initiative?
"The sponsor of this trial, Merck Sharp & Dohme Corp., is in search of a total 100 patients who meet the criteria to partake. Patients can be seen at AHN West Penn Hospital ( Site 0212) in Pittsburgh, Pennsylvania and Saint Louis University Cancer Center (Site 0209) in Saint Louis, Missouri amongst other locations."
Is recruitment still ongoing for this investigation?
"Affirmative. The information hosted on clinicaltrials.gov states that this medical research is currently recruiting volunteers, and was first posted in the 8th of January 2022 with an update made at 24th November 2022. To be precise, 100 individuals are desired to join from 16 different trial sites."
Share this study with friends
Copy Link
Messenger